The cost of Humira (adalimumab) for psoriasis can vary significantly based on several factors including insurance coverage, pharmacy, and geographic location. Without insurance, the list price for a one-month supply of Humira can range from approximately $5,000 to $6,500 USD.
How much does Humira cost with insurance?
With insurance, out-of-pocket costs for Humira can be substantially lower. Patients often pay a copay, which can range from $0 to a few hundred dollars per month, depending on their specific insurance plan and whether they have met their deductible. Pharmaceutical companies that manufacture Humira may also offer patient assistance programs or copay cards that can further reduce the financial burden for eligible individuals.
What are the patient assistance programs for Humira?
AbbVie, the manufacturer of Humira, offers the Humira Complete program, which provides financial assistance and support services to eligible patients. This program can include copay assistance for commercially insured patients and free medication for uninsured or underinsured patients who meet certain income criteria.
When does Humira's patent expire?
The patents protecting Humira have been subject to numerous legal challenges. While initial patents have expired, leading to the availability of biosimilars, other patents may still be in effect, influencing the timeline for broader generic competition. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceuticals. For Humira, biosimilars began entering the U.S. market in early 2023, following earlier introductions in Europe.
How do Humira biosimilars affect cost?
The introduction of biosimilars for Humira is expected to lead to lower prices for adalimumab treatments. Biosimilars are approved by regulatory agencies and are highly similar to the reference biologic drug, offering comparable safety and efficacy. As more biosimilars become available, competition increases, typically driving down the overall cost of treatment for psoriasis and other conditions treated with Humira.
What are the alternatives to Humira for psoriasis treatment?
Several other biologic medications are available for treating moderate to severe plaque psoriasis, offering alternatives for patients who do not respond to or tolerate Humira. These include drugs in different drug classes such as:
* IL-17 inhibitors (e.g., secukinumab, ixekizumab, brodalumab)
* IL-23 inhibitors (e.g., guselkumab, risankizumab, tildrakizumab)
* IL-12/23 inhibitors (e.g., ustekinumab)
* TNF-alpha inhibitors other than adalimumab (e.g., etanercept, infliximab, certolizumab pegol, golimumab)
The choice of an alternative medication depends on individual patient factors, including disease severity, other medical conditions, treatment history, and cost.
Sources:
[1] https://drugpatentwatch.com/